I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

Core Viewpoint - I-Mab has completed enrollment ahead of schedule in the first dose expansion cohort of the Phase 1b givastomig combination study, which is focused on treating gastric cancer with a bispecific antibody targeting CLDN18.2 [1][2] Group 1: Clinical Study Progress - The Phase 1b study includes a dose escalation study with 17 participants and a dose expansion study with 40 participants, with topline data expected in the second half of 2025 [1][7] - Enrollment in the first dose expansion cohort was completed months ahead of schedule, and recruitment momentum continues in the second expansion cohort [2][7] Group 2: Drug Mechanism and Potential - Givastomig is a bispecific antibody that targets CLDN18.2-positive tumor cells and activates T cells through the 4-1BB signaling pathway, showing promise for first-line treatment of metastatic gastric cancers [3] - The drug has demonstrated strong tumor-binding properties and anti-tumor activity in previous studies, with a potential for reduced toxicities compared to other 4-1BB agents [3] Group 3: Collaborative Development - The development of givastomig is a joint effort with ABL Bio, where I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio [4] Group 4: Company Overview - I-Mab is a U.S.-based global biotech company focused on precision immuno-oncology agents for cancer treatment, with operations in Rockville, Maryland, and Short Hills, New Jersey [5]